Androgen Deprivation Therapy, Exercise Therapy, Prostatic Neoplasms
Conditions
Brief summary
Exercise intervention for men with prostate cancer on androgen deprivation therapy.
Detailed description
The aim of the project is to investigate the effects of patient education and exercise intervention implemented in daily clinical practice for men with prostate cancer on androgen deprivation therapy * Functional capacity * Quality of life * Body composition * Blood pressure and to assess safety of progressive resistance training for participants with bone metastases.
Interventions
BEHAVIORALGroup based exercise
Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
Sponsors
Herlev Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a prostate cancer diagnosis on androgen deprivation therapy
Exclusion criteria
* Opioid demanding treatment for skeletal pain * Eastern Cooperative Oncology Group performance status \> 2 * Inability to perform floor and machine exercises independently
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 30second Chair-Stand test (30s-CST) | Baseline, 12 and 24 weeks | Test of functional capacity, measured as change |
| Change in Graded Cycling Test with Talk Test (GCT-TT) | Baseline, 12 and 24 weeks | Test of functional capacity, measured as change |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in Bloodpressure | Baseline, 12 and 24 weeks | Systolic and diastolic bloodpressure |
| change in QoL | Baseline, 12 and 24 weeks | European Organisation for Research and Treatment of Cancer (EORTC) cancer and prostate specific questionnaires: EORTC QLQC-30 version 3.0 and PR25 |
| Compliance assessed by attendance and continued exercise (yes/no) | Baseline, 12 and 24 weeks | — |
| Safety of exercise assessed by serious adverse events according to the FDA | Study period baseline - 24 weeks | — |
| change in Body composition | Baseline, 12 and 24 weeks | BMI, waist and hip circumference, waist-hip ratio. |
Countries
Denmark
Outcome results
None listed